Brazil conditionally clears Takeda drug portfolio purchase
Brazil’s competition authority has greenlit local drugmaker Hypera Pharma’s bid to purchase a portfolio of medications from Takeda Pharmaceutical after the company offered a “fix-it-first” structural remedy.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.